INTRODUCTION: Debate persists regarding the relationship between mucin expression and outcome in colon cancer. This arises due to discrepancy in the definition of mucinous adenocarcinoma and the combination of both colon and rectal cancers in analyses. This study examines the relationship between increased mucin production and outcomes in colon cancer. METHODS: Cases were classified according to the World Health Organization classification of mucinous adenocarcinoma of the colon. Accordingly, tumors were categorized as either (a) mucinous adenocarcinoma of the colon (greater than 50% of the extracellular matrix occupied by mucin) or (b) non-mucinous adenocarcinoma of the colon. Overall survival and disease-free survival were calculated. A stepwise Cox proportional hazards regression model was employed to determine the risk of death/disease recurrence. Kaplan-Meier estimates of overall survival and disease-free survival were plotted for each group and compared using a log-rank test. RESULTS: On univariate analysis, mucinous adenocarcinoma was associated with reduced risk of death (P = 0.01). On multivariate analysis, mucinous adenocarcinoma was also associated with reduced risk of death (hazard ratio (HR) 0.33, 95% confidence interval (CI) 0.14-0.79, P = 0.01). Kaplan-Meier estimates confirmed improved rate of survival in the mucinous vs. non-mucinous group (P = 0.01). Mucinous adenocarcinoma did not affect disease-free survival (HR 0.75, 95% CI 0.46-1.21, P = 0.22). A comparison of Kaplan-Meier estimates for systemic recurrence demonstrated significant increases in systemic recurrence in the group with no mucin production (P = 0.04) but not for locoregional recurrence (P = 0.24). CONCLUSIONS: Histopathological evidence of mucinous adenocarcinoma in colon cancer is associated with improved outcomes.
INTRODUCTION: Debate persists regarding the relationship between mucin expression and outcome in colon cancer. This arises due to discrepancy in the definition of mucinous adenocarcinoma and the combination of both colon and rectal cancers in analyses. This study examines the relationship between increased mucin production and outcomes in colon cancer. METHODS: Cases were classified according to the World Health Organization classification of mucinous adenocarcinoma of the colon. Accordingly, tumors were categorized as either (a) mucinous adenocarcinoma of the colon (greater than 50% of the extracellular matrix occupied by mucin) or (b) non-mucinous adenocarcinoma of the colon. Overall survival and disease-free survival were calculated. A stepwise Cox proportional hazards regression model was employed to determine the risk of death/disease recurrence. Kaplan-Meier estimates of overall survival and disease-free survival were plotted for each group and compared using a log-rank test. RESULTS: On univariate analysis, mucinous adenocarcinoma was associated with reduced risk of death (P = 0.01). On multivariate analysis, mucinous adenocarcinoma was also associated with reduced risk of death (hazard ratio (HR) 0.33, 95% confidence interval (CI) 0.14-0.79, P = 0.01). Kaplan-Meier estimates confirmed improved rate of survival in the mucinous vs. non-mucinous group (P = 0.01). Mucinous adenocarcinoma did not affect disease-free survival (HR 0.75, 95% CI 0.46-1.21, P = 0.22). A comparison of Kaplan-Meier estimates for systemic recurrence demonstrated significant increases in systemic recurrence in the group with no mucin production (P = 0.04) but not for locoregional recurrence (P = 0.24). CONCLUSIONS: Histopathological evidence of mucinous adenocarcinoma in colon cancer is associated with improved outcomes.
Authors: R Rosenberg; H Nekarda; F Zimmermann; K Becker; F Lordick; H Hofler; M Molls; J R Siewert Journal: J Surg Oncol Date: 2008-01-01 Impact factor: 3.454
Authors: Hakjung Kang; Jessica B O'Connell; Melinda A Maggard; Jonathan Sack; Clifford Y Ko Journal: Dis Colon Rectum Date: 2005-06 Impact factor: 4.585
Authors: Mirna H Farhat; Kassem A Barada; Ayman N Tawil; Doha M Itani; Hassan A Hatoum; Ali I Shamseddine Journal: World J Gastroenterol Date: 2008-12-07 Impact factor: 5.742
Authors: Niek Hugen; Gina Brown; Robert Glynne-Jones; Johannes H W de Wilt; Iris D Nagtegaal Journal: Nat Rev Clin Oncol Date: 2015-09-01 Impact factor: 66.675
Authors: Christopher J Hayes; Catriona M Dowling; Susan Dwane; Mary E McCumiskey; Shona M Tormey; B Anne Merrigan; John C Coffey; Patrick A Kiely; Tara M Dalton Journal: Biomicrofluidics Date: 2016-10-31 Impact factor: 2.800
Authors: Sare Hosseini; Ali Mohammad Bananzadeh; Roham Salek; Mohammad Zare-Bandamiri; Ali Taghizadeh Kermani; Mohammad Mohammadianpanah Journal: Ann Coloproctol Date: 2017-04-28
Authors: Rene Warschkow; Ignazio Tarantino; Felix J Huttner; Bruno M Schmied; Ulrich Guller; Markus K Diener; Alexis Ulrich Journal: Br J Cancer Date: 2016-03-15 Impact factor: 7.640